Amgen Inc. operates in the Healthcare sector, within the Biotechnology industry. Founded in 1980 in the United States, the company focuses on developing biologic medicines using advanced genetic and molecular technologies.

Amgen researches, manufactures, and commercializes therapies targeting chronic and complex diseases.

Its portfolio includes treatments in:

• Oncology.

• Nephrology.

• Cardiovascular diseases.

• Inflammation and immunology.

• Bone health.

• Biosimilar medicines.

The company serves hospitals, healthcare systems, specialty clinics, and pharmaceutical distributors across North America, Europe, Asia-Pacific, and Latin America.

Amgen’s performance is influenced by clinical trial outcomes, patent protection, regulatory approvals, competition from other biopharmaceutical companies, and biosimilar market expansion.

The company operates manufacturing facilities and research centers in multiple countries, supported by large-scale biologics production capabilities and global cold-chain distribution systems.

Amgen shares trade on the Nasdaq Stock Market under the ticker AMGN.

History and Development

Amgen was founded in 1980 in California under the name Applied Molecular Genetics, with the objective of applying recombinant DNA technology to develop innovative therapies.

In its early years, the company focused on building research capabilities and advancing its clinical pipeline.

Following its public listing in the early 1980s, Amgen expanded its research investment and introduced pioneering biologic treatments that strengthened its position in the biotechnology sector.

Over the decades, the company diversified into new therapeutic areas and expanded internationally through acquisitions and strategic partnerships.

In recent years, Amgen has emphasized biosimilar expansion, next-generation biologics, and advanced genetic platforms, while adapting to regulatory and competitive pressures in global pharmaceutical markets.

Additional Information

Amgen Inc. (United States) is listed on the Nasdaq and has a market capitalization of $234.87 billion, with shareholders equity totaling $11.69 billion.

The company employs approximately 31.500 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Amgen Inc. reported $38.10 billion in revenue, generating net income of $8.74 billion.

Key financial metrics include a P/E ratio of 26.86, a price-to-book (P/B) ratio of 20.10, and a trailing twelve-month dividend yield of 2.29%.

The company trades under the ticker AMGN.